bioRxivImmunology
HVEM structures and mutants reveal distinct functions of binding to LIGHT and BTLA/CD160
W. Liu, T.-F. Chou, S. C. Garrett-Thomson, G.-Y. Seo, E. Fedorov, U. A. Ramagopa, J. B. Bonanno, K. Kakugawa, H. Cheroutre, M. Kronenberg, S. C. Almo
Abstract
HVEM is a TNF (tumor necrosis factor) receptor contributing to a broad range of immune functions involving diverse cell types. It interacts with a TNF ligand, LIGHT, and immunoglobulin (Ig) superfamily members BTLA and CD160. Assessing the functional impact of HVEM binding to specific ligands in different settings has been complicated by the multiple interactions of HVEM and HVEM binding partners. To dissect the molecular basis for multiple functions, we determined crystal structures that reveal the distinct HVEM surfaces that engage LIGHT or BTLA/CD160, including the human HVEM:LIGHT:CD160 ternary complex, with HVEM interacting simultaneously with both binding partners. Based on these structures, we generated mouse HVEM mutants that selectively recognized either the TNF or Ig ligands in vitro. Knock-in mice expressing these muteins maintain expression of all the proteins in the HVEM network, yet they demonstrate selective functions for LIGHT in the clearance of bacteria in the intestine and for the Ig ligands in the amelioration of liver inflammation.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Computational Design of a Highly-Specific HVEM-Based Inhibitor of LIGHT Protein
Piotr Ciura, Pamela Smardz, … Adam K. Sieradzan·bioRxiv·Oct 10, 2023
- Structure of human cytomegalovirus UL144, an HVEM orthologue, bound to the B and T cell Lymphocyte Attenuator
A. Bitra, I. Nemcovicova, … D. M. Zajonc·bioRxiv·Mar 29, 2019
- Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors
C. Demerle, L. Gorvel, … D. Olive·bioRxiv·Nov 4, 2022
- TNFRSF14 (HVEM) is a novel immune checkpoint for cancer immunotherapy in humanized mice
N. Aubert, S. Brunel, … g. marodon·bioRxiv·Dec 1, 2020
- The Role Of HVEM And Its Interaction With BTLA And CD160 In B-Cell Lymphoma Progression
C. Yago-Diez de Juan·bioRxiv·Sep 1, 2019
- A bioactive soluble recombinant mouse LIGHT promotes effective tumor immune cell infiltration delaying tumor growth
María‐Luisa del Rio, Oscar-Mariano Nuero-Garcia, … José-Ignacio Rodríguez-Barbosa·Journal of Molecular MedicinePeer-reviewed·Jun 2, 2025